You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2024

Investigational Drug Information for SHR6390

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug SHR6390?

SHR6390 is an investigational drug.

There have been 42 clinical trials for SHR6390. The most recent clinical trial was a Phase 1 trial, which was initiated on July 19th 2019.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Melanoma. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Tianjin Medical University Cancer Institute and Hospital.

There are two US patents protecting this investigational drug and sixteen international patents.

Recent Clinical Trials for SHR6390
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)Hebei Medical University Fourth HospitalPhase 2
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyTianjin Medical University Cancer Institute and HospitalPhase 2
SNF Platform Study of HR+/ HER2-advanced Breast CancerFudan UniversityPhase 2

See all SHR6390 clinical trials

Clinical Trial Summary for SHR6390

Top disease conditions for SHR6390
Top clinical trial sponsors for SHR6390

See all SHR6390 clinical trials

US Patents for SHR6390

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SHR6390 ⤷  Sign Up Pyrimidine or pyridopyridone compound and application thereof GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (Guangdong, CN) ⤷  Sign Up
SHR6390 ⤷  Sign Up Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor JIANGSU HENGRUI MEDICINE CO., LTD. (Jiangsu, CN) SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (Shanghai, CN) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.